20.10.2023 • News
EU Commission Approves Pfizer’s Takeover of Seagen
The US pharmaceutical company Pfizer has been cleared to acquire Seagen, a biotech company focused on developing cancer treatments.
Seagen
20.06.2023 • News
FTC Intervention in Amgen-Horizon Deal Stuns Biopharma
The US Federal Trade Commission’s lawsuit to potentially block the $27.8 merger of Amgen and Horizon Therapeutics is creating heightened concern in the international biopharma sector.
15.03.2023 • News
Pfizer Takes Seagen for $43 Billion
Pfizer has agreed to acquire Seagen, a global biotech focused on developing cancer treatments, for $43 billion. The announcement comes just a couple of weeks after the Wall Street Journal reported that the two companies were in talks.
01.03.2023 • News
Pfizer in Talks to Take Cancer Biotech Seagen
Pfizer is in the early stage of talks to acquire Seagen (formerly Seattle Genetics), a US biotech focused on developing treatments for cancer, according to a report in the Wall Street Journal that cited people familiar with the matter. The purchase price could potentially be more than $30 billion.
